neurasic_egg.pnglogo_connect.png

Neurasic Therapeutics

was launched in June 2020 by adMare BioInnovations, Canada’s Global Life Sciences Venture, and AmorChem II Fund l.p., a leading early-stage venture capital fund, to advance research that aims to provide new opiate-sparing pain-relieving drugs.

ABOUT

Neurasic Therapeutics is based on breakthrough research from Dr. Philippe Séguéla, professor of neuroscience at McGill University in Montreal, that was validated and further advanced by adMare BioInnovations. Dr. Séguéla is a world-expert in ion channel biology and molecular pharmacology. His research lab at the Montreal Neurological Institute (the Neuro) is renowned for investigating genes, cells and circuits involved in pain perception and analgesia.

Neurasic’s potential drug therapy targets acid-sensing ion channels (ASICs), a gene family of neuronal receptors that play a role in multiple neurological disorders. Early research has shown that blocking ASICs elicits analgesia (the inability to feel pain) in chronic pain conditions, therefore eliminating the need for opiate-based drugs. Dr. Séguéla and adMare have developed a proprietary method to identify molecules that block the ASICs.

Demo

Partners

logo